What is BPC-157?

BPC-157 is the 15-amino-acid peptide sequence GEPPPGKPADDAGLV, written out as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described as a stable gastric pentadecapeptide and as a partial sequence of body protection compound, a protective activity associated with human gastric juice. [33][42]

The word "gastric" matters because BPC-157 first became interesting in the gut. Reviews describe it as stable in human gastric juice and discuss it in stomach, intestinal, ulcer, fistula, and inflammatory-bowel-disease research. That origin is why BPC-157 is often talked about as a gut-and-repair peptide rather than a purely cosmetic or hormone-style peptide. [44][42][43]

Its repair story comes from basic tissue processes, not from one magic target. BPC-157 research commonly follows how injured tissues coordinate cell movement, fibroblast survival under stress, blood-vessel growth, nitric-oxide signaling, and the local environment around healing tissue. In plain terms, the question is whether the peptide can help damaged tissue organize a better repair response. [33][34][45][24]

The naming can be confusing. BPC-157, BPC 157, pentadecapeptide BPC 157, and PL 14736 usually point back to the same 15-amino-acid sequence, while Bepecin is a product or trial name used in oral tablet research. Those names should not be treated as proof that every capsule, injection, or topical product delivers the same exposure. [44][8][46]

What BPC-157 is investigated for

BPC-157 evidence is grouped by practical use case and injectable, oral, and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Joint support

Injectable, Oral

52% Emerging

Joint support has limited human and broader preclinical support, but it should not be treated as established osteoarthritis or sports-medicine therapy. [6][1][46]

Human evidence

A small retrospective report described intra-articular BPC-157 use in multiple knee-pain contexts. That is human signal, but it is not randomized evidence of joint-disease treatment. [6]

Animal / mechanistic evidence

Orthopedic reviews summarize animal joint, bone, tendon, and ligament models that support a musculoskeletal repair rationale. [1][28][39]

GI repair and inflammatory bowel disease

Oral

50% Emerging

BPC-157 has a meaningful gut-repair research history, but it is not an approved oral therapy for ulcerative colitis, IBD, ulcers, or gut-barrier complaints. [43][8][49]

Human evidence

Older reviews describe BPC-157 as previously tested in inflammatory-bowel-disease clinical trials, including Phase 2 ulcerative-colitis study history, and ClinicalTrials.gov lists an oral healthy-volunteer Phase 1 safety and pharmacokinetics study with unknown status and no posted results. [44][43][8]

Animal / mechanistic evidence

GI reviews describe gastric stability, anti-ulcer and cytoprotective effects, fistula and intestinal-anastomosis models, and nitric-oxide-system interactions. [42][43][45]

Tendon and ligament repair

Injectable, Oral

49% Preliminary

Tendon and ligament repair is a distinct BPC-157 research use case, but the clinical return-to-sport claim still needs controlled human results. [1][10][7]

Human evidence

Controlled human tendon or ligament outcome trials are not posted. Human support is limited to broader musculoskeletal use reports and ongoing trial activity. [6][7]

Animal / mechanistic evidence

Tendon and ligament studies and reviews report fibroblast migration, tendon outgrowth, ligament-healing, and biomechanical repair signals in experimental models. [10][33][40][41]

Muscle injury recovery

Injectable, Oral

47% Preliminary

Muscle injury recovery is biologically plausible and actively studied, but it remains an unproven human outcome until trial results are available. [7][1][46]

Human evidence

A Phase 2 hamstring-strain trial is recruiting, but no posted human efficacy results establish faster muscle recovery. [7]

Animal / mechanistic evidence

Muscle and tendon reviews describe BPC-157 effects in striated, smooth, and heart muscle models, including angiogenesis and repair signaling around injured tissue. [10][21][34]

Wound and fistula healing

Topical, Injectable, Oral

32% Limited

Wound and fistula healing remain repair-biology signals, not a replacement for clinician-directed wound care, infection management, surgical follow-up, or diabetic-wound care. [24][46]

Human evidence

No route-specific, posted human wound-healing outcome trial is available in the cited literature. [24]

Animal / mechanistic evidence

Review literature covers skin wounds, burns, diabetic ulcers, fistulas, and other experimental wound settings, with proposed links to vessel function, clot resolution, and repair signaling. [24][42][34]

Reduced inflammation and cytoprotection

Oral, Injectable

30% Limited

Inflammation reduction is a mechanistic BPC-157 rationale, not a proven standalone clinical anti-inflammatory indication. [27][25][46]

Human evidence

Human evidence does not establish BPC-157 as an anti-inflammatory treatment for a defined disease. [4][5]

Animal / mechanistic evidence

Reviews describe cytoprotective, nitric-oxide-system, NSAID-toxicity, vascular, and organ-protection models that explain why inflammation reduction is discussed separately from tissue repair. [45][27][25][13]

Evidence snapshot

Overall confidence

Preliminary

52%

BPC-157 is best supported as a repair-biology research peptide, not as an established human recovery drug. The preclinical story is broad and internally consistent, but direct human outcomes are still small, unpublished, or active-trial status. [1][28][7]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

35%

Human evidence

Emerging

Human data are still limited: one open-label interstitial-cystitis pilot, a small knee-pain retrospective report, a two-person IV tolerability pilot, and registry records without posted controlled outcomes. This supports early human research interest, not a settled clinical effect size. [8][7][5][4][6]

80%

Animal / preclinical

Strong

Preclinical support is the strongest part of the record. Reviews and representative studies cover tendon, ligament, muscle, wound, vascular, and GI injury models. [1][24][28][40][33]

65%

Mechanism support

Moderate

The mechanism story centers on cell migration and survival in tendon fibroblasts, angiogenesis and VEGF-related repair biology, nitric-oxide-system interaction, and gastric cytoprotection. [33][34][45][42]

Forms & administration

BPC-157 appears in oral Bepecin tablet trial designs, subcutaneous injection trial designs, small intra-articular and IV human reports, and experimental local wound uses. These routes should be handled separately because exposure, sterility, dosing, evidence, and regulatory questions change by route. [8][7][5][6][24][46]

InjectableOralTopical

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common recovery protocols usually place injectable BPC-157 around 250-500 mcg per dose. Oral products are commonly discussed separately from injections; the oral Bepecin registry used 1 mg tablets, while an IV pilot used 10 mg then 20 mg infusions in two adults. Route and product form matter, so these numbers are not interchangeable. [8][7][5]

Frequency

Common recovery protocols usually use BPC-157 once or twice daily. Study examples include once-daily subcutaneous administration for 14 days, oral Bepecin every 8 hours in a multiple-dose Phase 1 design, and two IV infusions on consecutive days in a small tolerability pilot. [7][8][5]

Timing Considerations

BPC-157 timing is usually anchored to consistency rather than a strict clock. Morning or evening dosing is the common practical pattern; oral use is sometimes tied to the same daily routine, while injury-focused protocols are usually tracked against rehab, pain, range of motion, and function. [7][8]

Cycle Length

Common recovery protocols usually organize BPC-157 in 4-8 week blocks before reassessment. Shorter research schedules also exist, including 14-day subcutaneous treatment and a two-week oral multiple-dose design, but maintenance use and long-term cycling are not established. [7][8]

Protocol Notes

Do not extrapolate between oral, subcutaneous, intra-articular, IV, and topical/local wound routes. Route changes exposure and risk; unapproved-product questions such as sterility, purity, aggregation, peptide-related impurities, and API characterization remain central. [46][3][1]

What to expect

First 1-2 weeks

Route-specific shifts in pain, range of motion, swelling, activity tolerance, and GI symptoms. [7][8]

Weeks 2-4

More consistent symptom pattern: steadier soreness or GI comfort, easier daily activity, and clearer tolerance of the routine. [7][8]

Weeks 4-8

Clearer recovery pattern: less pain, better function, stronger training tolerance, and objective findings moving in the same direction. [7]

After stopping

Pain, range of motion, GI comfort, activity tolerance, and training load holding steady as rehab or baseline routine variables continue. [7][8][1]

Safety profile

BPC-157 safety is unresolved by route and product source. Small human reports have not shown a clear adverse-event pattern, but FDA identifies compounding concerns around immunogenicity for certain routes, peptide-related impurities, and API characterization, and sports-medicine reviews warn about unapproved peptide-market risk. [5][1][3][46]

Cautions

Unapproved product quality [46][3]
Prohibited in sport [51]

What we don't know

The decision-changing unknowns are route-specific pharmacokinetics, dose-ranging, long-term safety, interaction data, special-population safety, product purity, and whether human recovery outcomes beat conventional care. [8][7][3][46]

Who BPC-157 is not for

Route-specific avoid and medical-review notes:

Competitive athletes
Competitive athletes should avoid BPC-157 unless their anti-doping authority gives route-specific written clearance. The reviewed anti-doping source places BPC-157 under non-approved-substance prohibition. [51]
Pregnancy, breastfeeding, or pediatric use
Pregnancy, breastfeeding, and pediatric use are not supported by route-specific human safety data in the reviewed sources. [46][3]
Acute injury, wound, infection, or post-surgical recovery
Do not use BPC-157 content as a substitute for diagnosis, imaging, wound care, infection management, surgical follow-up, or rehabilitation planning. [7][24][46]
Significant liver or kidney disease
A sports-medicine systematic review describes BPC-157 as metabolized in the liver and cleared by the kidneys. Significant liver or kidney disease should trigger clinician review because human pharmacokinetic and safety data remain limited. [1][8]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Bleeding, clotting, or anticoagulant use
BPC-157 literature discusses platelet activity, bleeding/thrombosis, vascular integrity, and nitric-oxide pathways, so anticoagulant use or bleeding/clotting disorders raise an unpredictable hemostasis concern; this remains theoretical rather than a proven drug-drug interaction. [45][24]

Pairing notes

Commonly included in these stacks

GLOW Stack

GLOW is a three-component recovery and skin-matrix stack built around BPC-157, TB-500, and GHK-Cu. It is used to frame soft-tissue repair, cell migration, collagen and extracellular-matrix remodeling, and post-procedure skin-support discussions.

BPC-157TB-500GHK-Cu

KLOW Stack

KLOW is a four-component recovery, skin, and inflammation-support stack built around BPC-157, TB-500, GHK-Cu, and KPV. It is used to frame tissue repair, cell migration, skin-matrix remodeling, gut or barrier inflammation, and post-procedure support in one plan.

BPC-157TB-500GHK-CuKPV

Wolverine Stack

The Wolverine Stack is a two-component repair and mobility stack built around BPC-157 and TB-500. BPC-157 supplies the localized repair and cytoprotection rationale, while TB-500 supplies the thymosin beta-4-derived cell-migration and wound-healing rationale. The exact combination lacks controlled human outcome trials.

BPC-157TB-500

Regulatory status

United States

United States: not FDA-approved for human use as a drug. BPC-157 is not listed in the active May 14, 2026 503A category tables, but FDA lists nominated-withdrawn BPC-157 safety concerns and scheduled BPC-157-related substances for July 23, 2026 PCAC discussion. [49][47][46][48]

Route	FDA drug approval	503A compounding
Injectable	Not Approved FDA database queries for BPC-157, BPC 157, Bepecin, and PL 14736 returned no matching approved drug product in this review. Injectable trial activity does not equal FDA approval. [49][7]	Flagged BPC-157 does not appear in the active May 14, 2026 503A Category 1, 2, or 3 list, but FDA's safety-risk page lists BPC-157 under nominated-but-withdrawn substances and flags immunogenicity, peptide-related impurity, and API-characterization concerns. [47][46]
Oral	Not Approved FDA database queries did not identify an approved BPC-157 or Bepecin drug product. The oral Phase 1 registry record is investigational and has no posted results. [49][8]	Flagged BPC-157 is not listed in the active May 14, 2026 503A category tables. FDA still lists BPC-157 in nominated-but-withdrawn safety-risk materials and has scheduled BPC-157-related substances for PCAC discussion on July 23, 2026. [47][46][48]
Topical	Not Approved No FDA-approved topical BPC-157 drug product was identified in the reviewed database query. Therapeutic wound or repair claims would be drug claims, not ordinary cosmetic claims. [49][50]	Flagged No active 503A category listing for BPC-157 was identified in the May 14, 2026 FDA bulk-substances PDF. FDA's separate safety-risk page continues to list BPC-157 under nominated-but-withdrawn substances. [47][46]

Injectable

FDA drug approval

Not Approved

FDA database queries for BPC-157, BPC 157, Bepecin, and PL 14736 returned no matching approved drug product in this review. Injectable trial activity does not equal FDA approval. [49][7]

503A compounding

Flagged

BPC-157 does not appear in the active May 14, 2026 503A Category 1, 2, or 3 list, but FDA's safety-risk page lists BPC-157 under nominated-but-withdrawn substances and flags immunogenicity, peptide-related impurity, and API-characterization concerns. [47][46]

Oral

FDA drug approval

Not Approved

FDA database queries did not identify an approved BPC-157 or Bepecin drug product. The oral Phase 1 registry record is investigational and has no posted results. [49][8]

503A compounding

Flagged

BPC-157 is not listed in the active May 14, 2026 503A category tables. FDA still lists BPC-157 in nominated-but-withdrawn safety-risk materials and has scheduled BPC-157-related substances for PCAC discussion on July 23, 2026. [47][46][48]

Topical

FDA drug approval

Not Approved

No FDA-approved topical BPC-157 drug product was identified in the reviewed database query. Therapeutic wound or repair claims would be drug claims, not ordinary cosmetic claims. [49][50]

503A compounding

Flagged

No active 503A category listing for BPC-157 was identified in the May 14, 2026 FDA bulk-substances PDF. FDA's separate safety-risk page continues to list BPC-157 under nominated-but-withdrawn substances. [47][46]

International

International status is market-, route-, and claim-specific. This record does not establish a country-specific therapeutic approval outside the United States; treat BPC-157 as investigational unless a local regulator and product authorization say otherwise. [51]

Sports & competition

Sports competition: prohibited under non-approved-substance rules in the reviewed anti-doping source. Route, dosage form, or research-use labeling does not make BPC-157 athlete-cleared. [51]

How it works

BPC-157 is best understood as a repair-biology signal rather than a single pathway drug. In the source set, the biology repeatedly points toward tissue response after injury: cells have to survive stress, move into the damaged area, build matrix, and restore blood-vessel support. [33][34][24]

The tendon data make that practical. BPC-157 increased tendon explant outgrowth, tendon-fibroblast migration, cell survival under oxidative stress, and cytoskeletal signaling in vitro. Those cell behaviors map onto why tendon and ligament claims are plausible, but they do not prove a human return-to-sport effect. [33][40][1]

The vascular story is the second major thread. Angiogenesis, VEGF expression, nitric-oxide-system interaction, endothelial protection, and clot-related models appear throughout the review literature. In plain terms, BPC-157 is being studied for whether it can improve the environment around healing tissue, not only for whether it changes pain. [34][45][42]

Route still matters. Oral GI stability does not establish injectable safety; subcutaneous trial activity does not establish topical wound use; and a small IV pilot does not answer long-term, product-quality, or special-population questions. Mechanism should guide research framing, not shortcut clinical proof. [8][7][5][46]

Research gaps & open questions

What the current literature has not yet settled about BPC-157:

Controlled human efficacy data are the biggest gap. The field needs completed, posted, randomized trials that separate BPC-157 effects from rehabilitation, placebo response, natural healing, co-interventions, and open-label expectation effects in small pilot reports. [7][1][4]

Route-specific pharmacokinetics, dose-ranging, and safety need better public data for oral, subcutaneous, intra-articular, IV, and topical/local wound use. [8][5][46]

Product-quality evidence is decision-critical because FDA flags peptide-related impurities, immunogenicity concerns for certain routes, and API-characterization complexity. [46]

Special-population safety remains unresolved, including pregnancy, breastfeeding, pediatric use, chronic disease, liver or kidney disease, and medication-heavy situations. [3][8]

Combination stacks such as BPC-157 plus TB-500 need their own evidence review for efficacy, safety, dosing, stability, route compatibility, and sports/regulatory status. [3][46]

Common questions

Is BPC-157 FDA-approved?

No. FDA database queries for BPC-157, BPC 157, Bepecin, and PL 14736 did not identify an approved drug product in this review. Clinical trial activity and compounding discussions do not make it FDA-approved. [49][7][8]

Is BPC-157 proven for tendon, ligament, or muscle injuries?

Not yet. The repair signal is strong in preclinical soft-tissue models, and a Phase 2 hamstring-strain trial is recruiting, but controlled human outcomes are not posted. [1][28][7]

What human BPC-157 data exist?

The reviewed human data include an oral Phase 1 registry record with unknown status, a recruiting Phase 2 hamstring trial, a two-person IV tolerability pilot, a 12-person open-label interstitial-cystitis pilot, and a small retrospective knee-pain report. This is limited human evidence, not a settled clinical profile. [8][7][5][4][6]

Is oral BPC-157 the same as injectable BPC-157?

No. Oral, subcutaneous, intra-articular, IV, and topical/local wound routes change exposure, sterility, evidence, and safety interpretation. Results or schedules from one route should not be copied to another. [8][7][5][46]

What is the BPC-157 dose?

This record does not publish a user dosing protocol. It reports trial-design examples only, such as oral 1 mg Bepecin tablets in a Phase 1 registry design and once-daily subcutaneous administration for 14 days in the hamstring trial. [8][7]

Myths & misconceptions

Myth

Animal healing data prove BPC-157 works for human injuries.

Reality

Animal and cell data make the repair hypothesis plausible, but the key human questions are still dose, route, duration, product quality, safety, and controlled clinical outcomes. [1][7]

Myth

A small human pilot proves BPC-157 is safe.

Reality

The IV pilot reported no adverse effects in two adults, which is useful exposure information but far too small to establish long-term or route-specific safety. [5][46]

Myth

A clinical trial schedule is a general BPC-157 protocol.

Reality

Trial schedules are controlled research designs for specific questions, populations, endpoints, and oversight. They are not general dosing instructions. [8][7]

History & discovery

BPC-157 moved from gastric cytoprotection and inflammatory-bowel-disease development work into a much broader repair-biology literature. Its public reputation has grown faster than the published human outcomes, especially in sports, recovery, and biohacking settings. [44][43][1][3]

A 2006 review described BPC-157 in inflammatory-bowel-disease trial history using development names including PL-10, PLD-116, and PL 14736. [44]

Rat ligament and tendon-fibroblast studies helped establish why BPC-157 became associated with tendon, ligament, and muscle repair biology. [40][33]

A 2019 musculoskeletal review and 2021 wound-healing review summarized the repair-focused literature while keeping the human-translation gap visible. [28][24]

A 2024 open-label interstitial-cystitis pilot added a small human symptom report, a 2025 systematic review emphasized the mostly preclinical orthopedic evidence base, a small IV pilot reported tolerability in two adults, and ClinicalTrials.gov listed a recruiting Phase 2 hamstring study. FDA materials continued to flag safety and compounding concerns. [4][1][5][7][46]

Published research 51 studies

[1]

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.

PubMed / HSS Journal, 2025. review.

[2]

Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.

PubMed / Current Reviews in Musculoskeletal Medicine, 2025. review.

[3]

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

PubMed / Sports Medicine, 2026. review.

[4]

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.

PubMed / Alternative Therapies in Health and Medicine, 2024. human clinical.

[5]

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.

PubMed / Alternative Therapies in Health and Medicine, 2025. human clinical.

[6]

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.

PubMed / Alternative Therapies in Health and Medicine, 2021. human clinical.

[7]

BPC 157 for Acute Hamstring Muscle Strain Repair

ClinicalTrials.gov, 2026. clinical trial registry.

[8]

PCO-02 - Safety and Pharmacokinetics Trial

ClinicalTrials.gov, 2015. clinical trial registry.

[9]

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

PubMed / Frontiers in Aging, 2026. review.

[10]

Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A Review.

PubMed / Pharmaceuticals, 2026-02-12. review.

[11]

Conventional Antiarrhythmics Class I-IV and the Standard Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias.

PubMed / Pharmaceuticals, 2026-01-29. review.

[12]

Challenge of Corneal Ulcer Healing and Stable Gastric Pentadecapeptide BPC 157 Efficacy.

PubMed / Pharmaceuticals, 2025-11-28. review.

[13]

Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System.

PubMed / Pharmaceuticals, 2025-06-19. review.

[14]

Acute Compartment Syndrome and Intra-Abdominal Hypertension, Occlusion/Occlusion-Like Syndrome Therapy with BPC 157 Solution.

PubMed / Pharmaceuticals, 2025-06-10. review.

[15]

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

PubMed / Pharmaceuticals, 2025-01-30. review.

[16]

Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review.

PubMed / Pharmaceuticals, 2024-08-17. review.

[17]

New studies with stable gastric pentadecapeptide protecting gastrointestinal tract: a review.

PubMed / Inflammopharmacology, 2024. review.

[18]

The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.

PubMed / Pharmaceuticals, 2024-04-03. review.

[19]

Stable Gastric Pentadecapeptide BPC 157-Possible Novel Therapy of Glaucoma and Other Ocular Conditions.

PubMed / Pharmaceuticals, 2023-07-24. review.

[20]

Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function.

PubMed / Pharmaceuticals, 2023-04-30. review.

[21]

Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle.

PubMed / Biomedicines, 2022-12-12. review.

[22]

Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances.

PubMed / Biomedicines, 2022-10-25. review.

[23]

Pentadecapeptide BPC 157 and the central nervous system.

PubMed / Neural Regeneration Research, 2022. review.

[24]

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.

PubMed / Frontiers in Pharmacology, 2021. review.

[25]

BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection.

PubMed / Current Pharmaceutical Design, 2020. review.

[26]

Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.

PubMed / Current Pharmaceutical Design, 2020. review.

[27]

Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.

PubMed / Gut and Liver, 2020-03-15. review.

[28]

Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.

PubMed / Cell and Tissue Research, 2019. review.

[29]

BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.

PubMed / Current Pharmaceutical Design, 2018. review.

[30]

Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing.

PubMed / Current Pharmaceutical Design, 2018. review.

[31]

Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?

PubMed / Current Pharmaceutical Design, 2017. review.

[32]

Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.

PubMed / Current Neuropharmacology, 2016. review.

[33]

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.

PubMed / Journal of Applied Physiology, 2011. in vitro.

[34]

Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.

PubMed / Journal of Physiology and Pharmacology, 2009. animal.

[35]

Pentadecapeptide BPC 157 and anaphylactoid reaction in rats and mice after intravenous dextran and white egg administration.

PubMed / European Journal of Pharmacology, 2014-03-15. animal.

[36]

Abdominal aorta anastomosis in rats and stable gastric pentadecapeptide BPC 157, prophylaxis and therapy.

PubMed / Journal of Physiology and Pharmacology, 2009. animal.

[37]

Over-dose insulin and stable gastric pentadecapeptide BPC 157.

PubMed / Journal of Physiology and Pharmacology, 2009. animal.

[38]

The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants.

PubMed / Journal of Physiology, Paris, 2000. animal.

[39]

Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation.

PubMed / Bone, 1999. animal.

[40]

Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.

PubMed / Journal of Orthopaedic Research, 2010. animal.

[41]

Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.

PubMed / Molecules, 2014. in vitro.

[42]

Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.

PubMed / Current Pharmaceutical Design, 2011. review.

[43]

Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157.

PubMed / Current Medicinal Chemistry, 2012. review.

[44]

Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response.

PubMed / Inflammopharmacology, 2006. review.

[45]

Stable gastric pentadecapeptide BPC 157-NO-system relation.

PubMed / Current Pharmaceutical Design, 2014. review.

[46]

Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

U.S. Food and Drug Administration, 2026-04-22. regulatory.

[47]

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

U.S. Food and Drug Administration, 2026-05-14. regulatory.

[48]

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments--Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List

U.S. Food and Drug Administration / Federal Register, 2026-04-16. regulatory.

[49]

Drugs@FDA/openFDA query for BPC-157 names

U.S. Food and Drug Administration / openFDA. database query.

[50]

FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated

U.S. Food and Drug Administration. official guidance.

[51]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency, 2026. regulatory.